CN108096307A - Application of the eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared - Google Patents

Application of the eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared Download PDF

Info

Publication number
CN108096307A
CN108096307A CN201810045561.1A CN201810045561A CN108096307A CN 108096307 A CN108096307 A CN 108096307A CN 201810045561 A CN201810045561 A CN 201810045561A CN 108096307 A CN108096307 A CN 108096307A
Authority
CN
China
Prior art keywords
eupatorium
hepatitis
ethanol extract
trifoliolatum
lindley
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201810045561.1A
Other languages
Chinese (zh)
Other versions
CN108096307B (en
Inventor
张健
陈道峰
任慧玲
褚纯隽
李显伦
严彪
吴双庆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou University
Original Assignee
Suzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou University filed Critical Suzhou University
Priority to CN201810045561.1A priority Critical patent/CN108096307B/en
Publication of CN108096307A publication Critical patent/CN108096307A/en
Application granted granted Critical
Publication of CN108096307B publication Critical patent/CN108096307B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of application of eupatorium lindleynun var. trifoliolatum ethanol extract in anti-hepatic-B virus medicine is prepared.Eupatorium lindleynun var. trifoliolatum ethanol extract is prepared in the present invention from eupatorium lindleynun var. trifoliolatum, this its progress anti-hepatitis virus HBV experiment, the result shows that it is respectively provided with the effect for significantly inhibiting hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg, there is better pharmaceutical activity compared with treating the clinical medicine lamivudine (3TC) of hepatitis B.Eupatorium lindleynun var. trifoliolatum ethanol extract of the present invention can be used for the drug for preparing anti-hepatitis virus.

Description

Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine
Technical Field
The invention relates to an application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicines.
Background
Hepatitis B Virus (HBV) infection is one of main diseases affecting human health, about 3 hundred million people are chronic hepatitis B virus carriers worldwide, China is the country with the most hepatitis B virus carriers, about 0.93 hundred million people, acute hepatitis B is easy to be converted into chronic hepatitis, even deteriorates into cirrhosis and liver cancer, at present, domestic medicines for treating chronic viral hepatitis are mainly 1, orally taken nucleoside (acid) chemical medicines, such as lamivudine, adefovir, entecavir, telbivudine, tenofovir and the like, but easily generate drug resistance, 2, biological preparations, interferons, such as interferon α and pegylated interferon α, which are commonly used, but most patients have rebound phenomenon after drug withdrawal, and the interferon is expensive (about 2-4 yuan for each course of treatment), cannot be taken through gastrointestinal tract, is inconvenient to use, easily generates side effects after long-term administration, such as side effects of similar symptoms and traditional platelet reduction and the like, 3, traditional Chinese medicines, ziguo acid and derivatives thereof, polysaccharides, and plant chemical polysaccharides, and medicaments for improving liver diseases, especially the immune response of Japanese apricot yellow plum virus, the liver disease, the drug development of Japanese apricot kernel, the drug development, the drug metabolism, the liver disease, the research of China, the research of the medicine, the research of traditional Chinese medicine, the research of the.
Herba Eupatorii Lindleyanum DC of Compositae is herba Eupatorii Lindleyanum, and is prepared from herba Eupatorii Lindleyanum DC. Has bitter taste and mild nature, enters liver and spleen meridians, has the functions of eliminating phlegm and stopping cough, clearing heat and releasing toxin, inducing diuresis and reducing edema and reducing blood pressure, and is used for treating cold, cough and excessive phlegm, headache, tonsillitis, bacillary dysentery and hypertension (see: the national traditional Chinese medicine administration, Chinese materia medica, Shanghai: Shanghai science and technology publisher, 1999:7,6876). The extract of lindley eupatorium has the effect of protecting rats with acute lung injury, the compound lindley eupatorium capsule has a certain inhibiting effect on influenza viruses in vitro, the concentrated solution of lindley eupatorium syrup has a certain antibacterial effect on gram positive and negative bacteria and candida albicans, and the extract of lindley eupatorium total flavonoids has the effect of reducing blood viscosity (see: Jianzhou, Yanghui, Hoohai Xixia, etc. the extract of lindley eupatorium has a certain inhibiting effect on gram positive and gram negative bacteria and candida albicans. the research on the protective effect of lindley eupatorium on acute lung injury of rats, Chinese pharmacy 2007, 18 (27): 4; Zhou Dazhou, Wu Yan Jian, etc. the experiment research on the anti-influenza viruses of compound lindley eupatorium, Chinese patent medicine, 2008, 30 (5): 650-650, Wan Kejing, Qin Jiang, Cheng Zhun, etc. the research on the pharmacological and clinical effects of Chinese medicine, 2009, 25(2): 80-82. ) However, whether the lindley eupatorium has the effect of resisting the hepatitis B virus is not reported, and the invention finds that the lindley eupatorium has the activity of resisting the hepatitis B virus.
Disclosure of Invention
The invention aims to: provides an application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicaments.
The technical scheme of the invention is as follows: the application of lindley eupatorium herb in preparing the anti-hepatitis B virus medicine is that the lindley eupatorium herb is an ethanol extract of the lindley eupatorium herb, and the ethanol extract is obtained by adopting the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain the eupatorium lindleyanum ethanol extract.
The lindley eupatorium herb is a lindley eupatorium herb flavone part containing jaceosidin and eupatorium xanthophyll, and the chemical structural formulas of the lindley eupatorium herb are respectively as follows:
the lindley eupatorium is a lindley eupatorium sesquiterpene part containing lindley eupatorium lactone F, lindley eupatorium lactone G, lindley eupatorium lactone H, lindley eupatorium lactone I and lindley eupatorium lactone K; the chemical structural formula is as follows:
the lindley eupatorium herb is an eluted part of lindley eupatorium herb with 70% ethanol water, and is prepared by the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain an eupatorium lindleyanum ethanol extract; dissolving the extract in water to prepare a solution with the concentration of 0.5-1 g/ml, adsorbing the solution by weak-polarity macroporous adsorption resin, eluting by water to remove macromolecular compounds, eluting by 90-95% ethanol aqueous solution by volume fraction, and recovering the solvent at 40-60 ℃ under reduced pressure to obtain a macroporous resin part; adsorbing the obtained macroporous resin part by an ODS (oxide dispersion strengthened) reverse phase silica gel chromatographic column, eluting by 50% methanol aqueous solution by volume fraction, then eluting by 70% -75% methanol aqueous solution, recovering the solvent at 40-60 ℃ under reduced pressure, adsorbing by a 30-60 mesh polyamide chromatographic column, and eluting by 70% ethanol aqueous solution by volume fraction to obtain the lindley eupatorium 70% ethanol aqueous part.
Further, preferably, the weak polar macroporous absorption resin is AB-8, D101, HPD-100, HPD-200A, HPD-200B, HPD-300, HPD-700 or HPD-722 macroporous absorption resin;
further, preferably, the ODS reversed-phase silicA gel chromatographic column is A DAISOGEL ODS reversed-phase silicA gel filler with the particle size of 50-70 um, A Cosmsil ODS reversed-phase silicA gel filler with the particle size of 50-70 um or A YMCODS-A reversed-phase silicA gel filler with the particle size of 50-70 um;
furthermore, preferably, the volume ratio of the water to the low-polarity macroporous adsorption resin is 8-15: 1; the volume ratio of the 90-95% ethanol aqueous solution to the macroporous adsorption resin is 8-15: 1; the mass ratio of the volume of the ODS reversed phase silica gel chromatographic column to the obtained macroporous resin part is 20-30: 1; the volume ratio of the 50% methanol aqueous solution to the 70-75% methanol aqueous solution to the ODS reversed phase silica gel chromatographic column is 5-8: 1; the mass ratio of the volume of the polyamide chromatographic column to the adsorbed sample is 20-30: 1; the volume ratio of the 70% ethanol aqueous solution to the polyamide chromatographic column is 4-10: 1.
The lindley eupatorium is a lindley eupatorium medium-chain diterpenoid compound selected from (1)3- (hydroxymethy) -1, 14, 15-trihydroxy-7, 11, 15-trimethy-2, 6, 10-hexadecainen-13-acetate and (2)3- (hydroxymethy) -1, 13, 15-trihydroxy-7, 11, 15-trimethy-2, 6, 10-hexadecainen-14-acetate, and the structural formulas of the compounds are respectively as follows:
the four extracts and two chain diterpenoid compounds are subjected to in vitro anti-hepatitis B virus HBV experiments to obtain the extract which has obvious inhibition effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg, and the extract has obvious anti-hepatitis B virus HBV effect and can be used for preparing anti-hepatitis B virus medicines.
The invention has the advantage of providing a new source for anti-hepatitis B virus medicines.
Drawings
The invention is further described with reference to the following figures and examples:
FIG. 1 is a high performance liquid chromatogram of a tremula sesquiterpene locus of example 2;
FIG. 2 is a high performance liquid chromatogram of control Eupalinolide F in example 2;
FIG. 3 is a high performance liquid chromatogram of control Eupalinolide G of example 2;
FIG. 4 is the HPLC chromatogram of control substance Eupalinolide H in example 2;
FIG. 5 is a high performance liquid chromatogram of control Eupalinolide I in example 2;
FIG. 6 is a high performance liquid chromatogram of control Eupalinolide K in example 2;
FIG. 7 is a high performance liquid chromatogram of the lindley eupatorium herb flavone site in example 2;
FIG. 8 is the HPLC chromatogram of the control Eupatorium adenophorum xanthophyll in example 2;
FIG. 9 is a high performance liquid chromatogram of a control jaceosidin from example 2;
Detailed Description
The invention is further illustrated by the following examples.
Example 1: preparation method of herba Eupatorii Lindleyani extract and herba Eupatorii Lindleyani medium chain diterpene compound
(1) Weighing 1000g of eupatorium lindleyanum dry whole grass, cutting into sections of 2-3 cm, adding 15 times volume of 80% ethanol aqueous solution, carrying out reflux extraction for 2 hours, repeating the extraction for 2 times, recovering the solvent at 60 ℃ under reduced pressure to obtain 158g of eupatorium lindleyanum ethanol extract (EUP-EtOH), dissolving the EUP-EtOH) in about 150ml of water, adsorbing the eupatorium lindleyanum ethanol extract (EUP-EtOH) by 1800ml of AB-8 macroporous adsorption resin, eluting by 20000ml of water to remove macromolecular compounds, eluting by 20000ml of 95% ethanol aqueous solution at 60 ℃ under reduced pressure to recover the solvent to obtain 61g of macroporous resin parts; adsorbing the obtained macroporous resin part with 1500ml Cosmsil ODS reversed phase silica gel column with particle size of 70um, eluting with 10000ml methanol water solution with volume fraction of 50%, and recovering solvent under reduced pressure at 60 deg.C to obtain 21g of Eupatorium eupatorium sesquiterpene part (EUP-SQT). Then 10000ml of 70% methanol aqueous solution is used for elution, the solvent is recycled under reduced pressure at 60 ℃ to obtain 20g of extract, the extract is absorbed by 600ml of 30-60 mesh polyamide chromatographic column, 4000ml of 70% ethanol aqueous solution is used for elution, and the solvent is recycled under reduced pressure at 60 ℃ to obtain 14.7g of lindley eupatorium 70% ethanol aqueous elution part (EUP-DIT). Eluting with 4000ml 100% ethanol, and recovering solvent at 60 deg.C under reduced pressure to obtain 2.8g of herba Eupatorii Lindleyani flavone fraction (EUP-FLA).
(2) Preparation of lindley eupatorium chain diterpene compound: drying herba Eupatorii Lindleyani 2000g, extracting with 10 times of 80% ethanol-water under reflux for 2 times, each for 2 hr, mixing filtrates, and recovering ethanol under reduced pressure to obtain 250g extract; dissolving the extract in 100mL of water, extracting with 100mL of petroleum ether for degreasing, extracting with chloroform twice (100 mL each time), and concentrating the chloroform extraction layer at 30 deg.C under reduced pressure to obtain about 11g of chloroform; the chloroform fraction was subjected to 300g of silica gel column chromatography and eluted with chloroform-methanol 100:2 to give 1.08g of an eluted fraction. Performing column chromatography with 200mL Rohm and Haas resin column, eluting with 60% -80% methanol-water system, collecting 0.5g of 80% methanol eluate, performing silicA gel column chromatography, eluting with chloroform-methanol (50:1) to obtain 112mg of 2A, preparing 2A with high performance liquid chromatography, preparing chromatograph with Beijing Huideyi ILC-P3050, chromatographic column YMC-PackODS-A column (250mm £ 20mm, YMC, Kyoto, Japan), detecting wavelength of 210nm, eluting with 70% methanol-water system, separating at flow rate of 5mL/min for 38.5min to obtain 31mg of compound (A), and separating at 42.8min to obtain 26mg of compound (b).
Example 2: detection of sesquiterpene fraction, flavone fraction and active ingredient of mid-chain diterpene compound
(1) Detecting active ingredients of Eupatorium eupatorium sesquiterpene part (EUP-SQT): in this example, the components were determined by HPLC. High performance liquid chromatography (Agilent 1260Infinity, Agilent, usa) wherein mobile phase a is acetonitrile; the mobile phase B is water; the mobile phase conditions are shown in table 1. A chromatographic column: YMC-PACK ODS-A (phi 4.6 mm. times.250 mm,5 μm); column temperature: 28 ℃; detection wavelength: 210 nm; sample introduction amount: 20 mu l of the mixture; flow rate: 1 ml. min-1
TABLE 1 HPLC chromatographic analysis conditions
Time (min) Mobile phase A (%) Mobile phase B (%)
0 30 70
5 30 70
15 32 68
25 36 64
40 36 64
6.02mg of reference substances, namely eupalinolide F, 14.94mg of eupalinolide G, 5.08mg of eupalinolide H, 10.04mg of eupalinolide I and 13.98mg of eupalinolide K are precisely weighed respectively, and the volume is fixed to 10ml by using a mobile phase A to serve as a stock solution. Adding mobile phase A, diluting to 1:2, 1:4, 1:8, 1:16 and 1:32, filtering with 0.22 μm filter membrane, and filtering to obtain filtrate. 5 concentrations of control were chromatographed and a standard curve was plotted, with 3 replicates per concentration point. Recording peak areas of the chromatographic peaks, and performing linear regression on the concentration (x) of the chromatographic peaks by using peak areas (y) of a reference substance to obtain a standard curve of the reference substance, wherein eupalinolide F, y is 63403 x-15.408; eupalinolide G, y 24720 x-20.065; eupalinolide H, y 79063x + 6.7811; eupalinolide I, y 239018x + 53.303; eupalinolide K, y 7913.5x + 62.857.
The EUP-SQT 6mg of eupatorium sesquiterpene prepared in example 1 was precisely weighed, the volume was determined to 10ml by mobile phase a volumetric flask, and the filtrate was filtered through a 0.22 μm membrane filter and subjected to chromatography.
FIGS. 1-6 are HPLC chromatograms of sesquiterpene positions (EUP-SQT) from Eupatorium, control products eupalinolide F, eupalinolide G, eupalinolide H, eupalinolide I and eupalinolide K.
By analyzing the high performance liquid chromatography result, eupatorium pseudochinensis (EUP-SQT) part samples containing eupatorium pseudochinensis F (eupatorium pseudochinensis F), eupatorium pseudochinensis G (eupatorium pseudochinensis G), eupatorium pseudochinensis H (eupatorium pseudochinensis H), eupatorium pseudochinensis I (eupatorium pseudochinensis I) and eupatorium pseudochinensis K (eupatorium pseudochinensis K) can be obtained, the chromatographic signal values of the samples are substituted into a standard curve, and the specific content of each component is further obtained, and the specific content is shown in Table 2.
TABLE 2 Eupatorium lappacans sesquiterpene fraction (EUP-SQT) sample containing 5 Eupatorium lappacans lactone
Sample (I) eupalinolide F eupalinolide G eupalinolide H eupalinolide I eupalinolide K Ratio of
Content (wt.) 4.1% 31.8% 6.8% 3.4% 47.7% 93.8%
(2) Detecting active ingredients of eupatorium lindleyanum flavone part (EUP-FLA): the method is similar to the detection of active ingredients of Eupatorium eupatorium sesquiterpene part. The conditions of the high performance liquid chromatography are as follows: mobile phase a was acetonitrile (containing 0.1% formic acid); mobile phase B was water (containing 0.1% formic acid); mobile phase conditions: see table 3; a chromatographic column: YMC-PACKODS-A (Φ 4.6 mm. times.250 mm,5 μm); column temperature: 28 ℃; detection wavelength: 365 nm; sample introduction amount: 20 mu l of the mixture; flow rate: 1 ml. min-1
TABLE 3 HPLC chromatogram analysis conditions
Time (min) Mobile phase A (%) Mobile phase B (%)
0 36 64
15 36 64
30 90 10
Precisely weighing control substances of eupatorium lucolium xanthophyll 4.67mg and jaceosidin 8.17mg respectively; and adding mobile phase A to a constant volume of 10ml to obtain stock solution, diluting with mobile phase A to obtain 1:2, 1:4, 1:8, 1:16 and 1:32, and filtering with 0.22 μm filter membrane to obtain filtrate. 5 concentrations of control were chromatographed and a standard curve was plotted, with 3 replicates per concentration point. Recording the peak area of each chromatographic peak, and performing linear regression on the concentration (x) by using the peak area (y) of a reference substance to obtain a standard curve of the reference substance, wherein eupatilin y is 52964x +19.30, and jaceosidin y is 55161x + 210.79.
6mg of the EUP-FLA sample of the eupatorium lindley EUP prepared in example 1 is precisely weighed, the volume is determined to 10ml by using the mobile phase A, the solution is filtered by a 0.22 mu m filter membrane, and the filtrate is respectively taken for chromatographic determination.
FIGS. 7-9 are high performance liquid chromatograms of a sample of Eupatorium odoratum flavone, a control of eupatilin, and a control of jaceosidin.
Analyzing by high performance liquid chromatography to obtain eupatorium adenophorum xanthophyll and jaceosidin in the sample of eupatorium adenophorum flavone part, and substituting the chromatographic signal value of the sample into a standard curve to further obtain the specific content of each component, as shown in Table 4.
TABLE 4 content of 2 flavones in Eupatorium lindleyanum flavone part
Sample (I) Eupatorium xanthophyll Jaceosidin Total ratio of
Content (wt.) 26.0% 66.1% 92.1%
(3) Detection of active ingredients of eupatorium lindleyanum medium-chain diterpenoid compounds: the compound (a) and the compound (b) prepared in example 1 were measured for spectrum, and the spectrum data were as follows:
the compound (a) is colorless oil, and the infrared spectrum IR (KBr) shows vmax:3424,2974,2930,1717,1653,1373,1258,1024cm-1(ii) a HR-ESI-MS gives the molecular ion peak M/z 421.2568[ M + N [ ]a]+(calcd forC22H38O6Na, 421.2561), indicating that its molecular formula is C22H38O6. It is composed of1H NMR and13c NMR spectra in CDCl3The measurement in (1). The results are shown in Table 1;
the compound (b) is colorless oil, and the infrared spectrum IR (KBr) shows vmax:3402,2972,2932,1653,1576,1418,1051,1015cm-1(ii) a HR-ESI-MS gives the molecular ion peak M/z 421.2565[ M + Na ]]+(calcd.forC22H38O6Na, 421.2561), indicating that its molecular formula is C22H38O6. It is composed of1H NMR and13c NMR spectra in CDCl3The measurement in (1). The results are shown in Table 5 below,
TABLE 5 preparation of the compounds (a), (b)1H NMR and13c NMR spectrum data
Wherein,1h NMR and13c NMR was performed at 400MHz and 125MHz, respectively.
By infrared spectrum, HR-ESI-MS and,1H NMR and13data analysis of C NMR spectra, in comparison with literature (see: Shuangqing Wu, Naiyu Xu, Jian Zhang, Shi Yao, Chunjun Chu. three new antibacterial reagents from Eupatorium linleyanum DC.. Journal of Asian Natural product research.2012,14(7):652-656.), consistent spectroscopic data, indicates: compound (a) is compound (1): 3- (hydroxymethy) -1, 14, 15-trihydroxy-7, 11, 15-trimethyl-2, 6, 10-hexadecacarrien-13-acetat, and the structural formula of the compound is as follows:
compound (b) is compound (2): 3- (hydroxymethy) -1, 13, 15-trihydroxy-7, 11, 15-trimethyl-2, 6, 10-hexadecacarrien-14-acetate, the structural formula of the compound is as follows:
example 3: external anti-HBV experiment of four eupatorium lindleyanum extracts and eupatorium lindleyanum medium-chain diterpene compounds
1. Experimental drugs and reagents: the chain diterpene compounds (1) and (2) were prepared in the above example 1; dimethyl sulfoxide; MTT (thiazole blue), shanghai jianlai biotechnology limited; control drug, lamivudine tablet (3 TC); kurarin Schk pharmaceuticals (Suzhou) Inc.; a cell culture medium DMEM, a growth medium and a preparation, wherein the growth medium contains 10% fetal calf serum, 380 mug/ml G418, 0.03% glutamine, penicillin, streptomycin and the like, and each 100 mug/ml;
2. experimental equipment: ELISA kit for detecting hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg; an incubator; 24-well plates, and the like.
3. Cell lines: 2.2.15 cell line of Hep G2, department of education/Ministry of health, molecular virology focus laboratory, Shanghai.
4. The experimental method comprises the following steps:
a2.2.15 cell line of Hep G2 was collected at 10X 10 cells per well5Individual cells were seeded in 24-well plates at 5% CO2Culturing at 37 ℃ in an incubator, after 48 hours, respectively replacing the growth liquid with drug culture liquids containing the compound (1) and the compound (2) which are dissolved by dimethyl sulfoxide, setting 5 concentrations of each group of drug culture liquids to be 12.5 mu g/ml-200 mu g/ml (as shown in table 2), setting 4 parallel holes for each concentration, continuing culturing for 9 days, and replacing the liquid once every 3 days. Positive control groupThe drug is lamivudine (3TC), the culture solution without drug is used as a blank control group, 1 hole is respectively arranged on each of the two control groups, and the operation of the two control groups is the same as that of the drug culture solution except that the growth solution is correspondingly changed into the lamivudine drug and the culture solution without drug. Collecting supernatant, detecting the content of HBsAg and HBeAg by using an ELISA kit, and simultaneously determining the toxicity of the two groups of compounds on cells by using MTT (methyl thiazolyl tetrazolium) at different concentrations. The results are shown in Table 6.
The above experimental procedures were repeated with ethanol extract of Eupatorium Adianum, Eupatorium Adianum flavone fraction, Eupatorium Adianum sesquiterpene fraction, and Eupatorium Adenanum 70% ethanol eluted fraction, respectively, to obtain the results shown in Table 6.
As can be seen from Table 6, both the chain diterpene compounds (1) and (2) had inhibitory effects on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg. The compounds (1) and (2) inhibit HBsAg and HBeAg, and the inhibition rate increases with the increase of concentration; when the compound (1) is at 50 mu g/mL, the inhibition rate of the compound on HBsAg and HBeAg is obviously higher than 3 TC; under the same concentration of the compound (2) and the 3TC, the inhibition rate of the compound (2) on HBsAg and HBeAg is obviously higher than that of the 3 TC; the compounds (1) and (2) at low concentrations had a high inhibitory rate against HBsAg and HBeAg as compared with 3 TC.
The ethanol extract, flavone part, sesquiterpene part, and 70% ethanol-eluted part of Eupatorium Adianum have effects of inhibiting HBsAg and HBeAg, and increasing the inhibition rate with increasing concentration; compared with 3TC, the low-concentration Eupatorium Adenophorum hand Mazz extract, Eupatorium Adenophorum hand Mazz fraction, and Eupatorium Adenophorum hand Mazz fraction with 70% ethanol elution fraction all have high inhibitory effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg.
TABLE 6 anti-HBV test results of four groups of Eupatorium Adenophorum extracts and two groups of chain diterpene compounds
Wherein, the ratio of +: "show toxicity" means a cell viability of < 75%; /: no inhibition rate test was performed.
The above examples can obtain that the drug prepared by extracting the lindley eupatorium ethanol extract, the lindley eupatorium flavone part, the lindley eupatorium sesquiterpene part, the lindley eupatorium 70% ethanol water elution part and the two chain diterpenoid compounds from the lindley eupatorium shows obvious inhibition effect on hepatitis B surface antigen HBsAg and hepatitis B core antigen HBeAg in an in vitro anti-hepatitis B virus HBV experiment, and has better drug activity compared with the clinical drug lamivudine (3TC) for treating hepatitis B. Therefore, the ethanol extract, the flavonoid part, the sesquiterpene part, the 70% ethanol water elution part and two chain diterpene compounds extracted from the lindley eupatorium herb can be used for preparing the anti-hepatitis B virus medicines.

Claims (1)

1. An application of an ethanol extract of lindley eupatorium in preparing anti-hepatitis B virus medicines is characterized in that the ethanol extract is obtained by adopting the following method: taking dry eupatorium lindleyanum whole grass, cutting the eupatorium lindleyanum into sections of 2-3 cm, adding 8-15 times of ethanol aqueous solution with volume fraction of 60-95%, refluxing and extracting for 1-3 hours, repeating for 1-3 times, and recovering the solvent under reduced pressure at 40-60 ℃ to obtain the eupatorium lindleyanum ethanol extract.
CN201810045561.1A 2014-06-04 2014-06-04 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine Active CN108096307B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810045561.1A CN108096307B (en) 2014-06-04 2014-06-04 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810045561.1A CN108096307B (en) 2014-06-04 2014-06-04 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine
CN201410244607.4A CN104069145B (en) 2014-06-04 2014-06-04 Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410244607.4A Division CN104069145B (en) 2014-06-04 2014-06-04 Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared

Publications (2)

Publication Number Publication Date
CN108096307A true CN108096307A (en) 2018-06-01
CN108096307B CN108096307B (en) 2021-02-05

Family

ID=51591011

Family Applications (5)

Application Number Title Priority Date Filing Date
CN201810045561.1A Active CN108096307B (en) 2014-06-04 2014-06-04 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine
CN201810045547.1A Active CN108245501B (en) 2014-06-04 2014-06-04 Application of chained diterpene compound of lindley eupatorium in preparing anti-hepatitis B virus medicine
CN201810045554.1A Active CN108159099B (en) 2014-06-04 2014-06-04 Application of eupatorium sesquiterpene part in preparation of anti-hepatitis B virus medicine
CN201410244607.4A Active CN104069145B (en) 2014-06-04 2014-06-04 Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared
CN201810046069.6A Active CN108113985B (en) 2014-06-04 2014-06-04 Application of eupatorium lindleyanum flavone part in preparation of anti-hepatitis B virus medicines

Family Applications After (4)

Application Number Title Priority Date Filing Date
CN201810045547.1A Active CN108245501B (en) 2014-06-04 2014-06-04 Application of chained diterpene compound of lindley eupatorium in preparing anti-hepatitis B virus medicine
CN201810045554.1A Active CN108159099B (en) 2014-06-04 2014-06-04 Application of eupatorium sesquiterpene part in preparation of anti-hepatitis B virus medicine
CN201410244607.4A Active CN104069145B (en) 2014-06-04 2014-06-04 Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared
CN201810046069.6A Active CN108113985B (en) 2014-06-04 2014-06-04 Application of eupatorium lindleyanum flavone part in preparation of anti-hepatitis B virus medicines

Country Status (1)

Country Link
CN (5) CN108096307B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108096307B (en) * 2014-06-04 2021-02-05 苏州大学 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine
CN105288513A (en) * 2015-12-07 2016-02-03 包永昌 Traditional Chinese medicine composition for treating hepatitis B and cirrhosis
CN106309529B (en) * 2016-10-25 2019-11-12 南京中医药大学 A kind of preparation method of eupatorium lindleynun var. trifoliolatum active component
CN116354912B (en) * 2021-12-27 2023-11-14 杭州亦坚生物医药科技有限公司 Compound and application thereof in serving as or preparing ABCG2 agonist

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003681A2 (en) * 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
CN1486699A (en) * 2003-09-04 2004-04-07 江苏省中医药研究院 Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine
CN1785174A (en) * 2005-11-09 2006-06-14 中国药科大学 Application of wogonin for preparing medicine to treat or prevent hepatitis B
CN103340916A (en) * 2013-07-18 2013-10-09 重庆市中药研究院 Lindley eupatorium extract as well as preparation method and application thereof
CN103520153A (en) * 2013-10-22 2014-01-22 苏州大学 Application of Eupalinolide K in preparing anticomplement drugs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02138289A (en) * 1988-08-29 1990-05-28 Nippon Mektron Ltd Novel diterpenoid glycoside preventive and improver for hypertension comprising same glycoside as medicinal component and production thereof
DE19644422C2 (en) * 1996-10-25 2000-06-15 Stefan Schulz Use of terpenes to treat autoimmune diseases and graft rejection
CN100515230C (en) * 2006-01-12 2009-07-22 重庆佳易医疗器械有限公司 New medicinal use of eupatorium lindleyanun
JP2013071901A (en) * 2011-09-27 2013-04-22 Saishunkan Seiyakusho:Kk Cosmetic for inhibiting melanin production
CN102389456A (en) * 2011-11-29 2012-03-28 苏州大学 Method for extracting isodon japonica var.galaucocalyx total diterpenoids or Glaucocalyxin A
CN103142628A (en) * 2013-02-05 2013-06-12 广西壮族自治区药用植物园 Application of diterpenoid compound in treating hepatitis c virus (HCV)
CN103191386B (en) * 2013-03-22 2014-04-30 刘晓燕 Medicament for treating chronic hepatitis B
CN103655544B (en) * 2013-12-02 2016-03-30 滨州医学院 The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI
CN108096307B (en) * 2014-06-04 2021-02-05 苏州大学 Application of lindley eupatorium herb ethanol extract in preparing anti-hepatitis B virus medicine
CN107243005A (en) * 2017-05-04 2017-10-13 浙江中医药大学 A kind of anti-cancer composition extracted from eupatorium lindleynun var. trifoliolatum and its preparation method and application

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003681A2 (en) * 1999-07-08 2001-01-18 Prendergast Patrick T Use of flavones, coumarins and related compounds to treat infections
CN1486699A (en) * 2003-09-04 2004-04-07 江苏省中医药研究院 Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine
CN1785174A (en) * 2005-11-09 2006-06-14 中国药科大学 Application of wogonin for preparing medicine to treat or prevent hepatitis B
CN103340916A (en) * 2013-07-18 2013-10-09 重庆市中药研究院 Lindley eupatorium extract as well as preparation method and application thereof
CN103520153A (en) * 2013-10-22 2014-01-22 苏州大学 Application of Eupalinolide K in preparing anticomplement drugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
吴双庆,等: "野马追化学成分", 《中国中药杂志》 *

Also Published As

Publication number Publication date
CN104069145B (en) 2018-04-27
CN108159099A (en) 2018-06-15
CN108159099B (en) 2021-03-26
CN108113985B (en) 2020-07-21
CN108096307B (en) 2021-02-05
CN108245501B (en) 2020-07-24
CN108245501A (en) 2018-07-06
CN108113985A (en) 2018-06-05
CN104069145A (en) 2014-10-01

Similar Documents

Publication Publication Date Title
CN101062071B (en) Total saponins from radix bupleuri extract and the preparing method thereof
CN104257715B (en) Herba Artemisiae extract and its preparation method and application
CN100998621B (en) Radix sileris total chromone extractive and its preparation method
CN101073595A (en) Glycyrrhiza total flavonoid and total saponin extract and its production
CN101863871B (en) Total glycosides of Rhodiola rosea, medical application and preparation method thereof
CN101062078A (en) Extract of stevia whole stevioside and stevia whole flavone and the preparing method thereof
CN101062069A (en) Whole coumarins extract from root of dahuriae angelica and the preparing method thereof
CN104069150B (en) Preparation method of honeysuckle extract
CN104069145B (en) Application of the eupatorium lindleynun var. trifoliolatum in anti-hepatic-B virus medicine is prepared
CN102286056A (en) Oleanolic acid derivative and preparation method thereof
CN103819445A (en) Method for preparing two neo-pentenyl flavonoid compounds with hypolipidemic activity in fructus podophylli
CN104370871B (en) The mouth diphenylene ketone oxide class separated from Swertia punicea Hemsl. and the application of suppression hepatitis B virus
CN101856435B (en) Preparation method and content determination method of Daphne giraldii Nitsche total coumarin extract
CN102688261A (en) Pteris multifida extract, preparation method thereof and use thereof
CN109232491A (en) The Preparation method and use of benzofuran compounds in a kind of Herba Serissae
CN104027403B (en) A kind of preparation method of Radix Polygalae sugar ester effective site
CN107129478B (en) Semi-terpene lactone compound and preparation method and application thereof
CN104398950A (en) Four-flavored calamus anticancer extract, as well as preparation method and application of four-flavored calamus anticancer extract
CN102670698B (en) The application of Radix Flemingiae Philippinensis extract in preparation control diabetes medicament
CN101816702B (en) Lung cancer preventing and treating composition extracted from selfheal and/or garden orache and application thereof in preparation of lung cancer preventing and treating medicine
CN104983789A (en) Separating method for fine active dracocephalum heterophyllum component and application of fine active dracocephalum heterophyllum component
CN108096302A (en) A kind of Herba Rostellulariae extract of platelet aggregation-against and its preparation method and application
CN104586925B (en) Redback christmashush root extract and preparation method and preparation treatment hepatitis B medicine application
TWI685345B (en) Artemisia extracts for inhibiting lung cancer cells
CN102526154B (en) Method for preparing antitumor medicine burdock root extractive

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant